Board of Directors
Sherine M. Abdelmawla, Ph.D. (Co-founder and CEO): Sherine has over 11 years of experience working in academia, and the biotechnology and pharmaceutical industries; within R&D and clinical divisions; to develop HCV inhibitors, nucleic acid based cancer therapeutics, and cancer diagnostics. Sherine serves on few boards including MatchBox Co-working Board of Directors and Ivy Tech Community College, Chemical Technology Advisory Board. Sherine holds a Ph.D. in Medicinal Chemistry and Molecular Pharmacology from Purdue University and a B.S. degree with honors in Pharmaceutical Sciences from Cairo University, School of Pharmacy where she held a faculty position until 2014.
Mohammad N. Noshi, Ph.D. (Co-founder, President of R&D and COO): Noshi has over 10 years of experience within the academic and industrial settings developing chemistry methodologies, synthesis of anti-cancer natural products, complex alkaloids synthesis, diagnostic agents for image guided surgery in cancer, and potential drug candidates for Alzheimer 's disease and prostate cancer. Noshi holds Ph.D. in Organic Chemistry from Purdue University, postdoctoral experience from MIT, M.S. in Medicinal Chemistry from The University of Toledo, and a B.S. with honors in Pharmaceutical Sciences from Cairo University where he held a faculty position.
John Bamforth, Ph.D. : Dr. Bamforth has been a highly successful executive for over 30 years in pharmaceutical and life sciences industry. He held a number of cross-functional roles and is best known for his successes in an array of commercial roles. These experiences include broad global strategy roles building blockbuster brands, such as Cialis. He was instrumental to the success of the largest restructure in Lilly’s history in 2013. Dr. Bamforth has recently retired as Vice President and Chief Marketing Officer for Lilly’s Biomedicines business Unit, a $6B business that operated across three therapeutic areas; immunology, pain/migraine and neuro-degeneration, primarily Alzheimer’s disease. Alongside a focus on building and launching six new blockbuster brands, he has been active in business development, most notably the recent $960M acquisition of CoLucid to access lasmiditan, a novel treatment for migraine. He has delivered outstanding business results across Europe, the US, Japan and China, including successful launches of several medicines in neuroscience, diabetes, urology, immunology and cardiovascular disease. These launches have often been through partnerships with companies large and small. He is the Lilly chair of a partnership with Pfizer in the development of a chronic pain brand and has lead launches with biotech companies such as ICOS, United Therapeutics and Acrux. He received his bachelor degree in Pharmacy from the University of Bath and his Ph.D. in neuropharmacology from Aston University in the United Kingdom. Pharmavoice named John one of Pharma’s top 100 ‘Inspirational Leaders’ in 2007 and Aston University awarded him an Honorary Doctorate for service to the Pharma Industry in 2012.
Elevate Ventures: Non-voting Board member